Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HRS 2189

Next Previous
X
Search
Drug Profile

HRS 2189

Alternative Names: HRS-2189

Latest Information Update: 24 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shandong Suncadia Medicine
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 18 Dec 2024 Fudan University plans a phase II trial for Prostate cancer (Metastatic disease, Combination therapy) in China (PO) (NCT06738745)
  • 07 Nov 2024 Shandong Suncadia Medicine plans a phase Ib/II trial for Breast cancer (Combination therapy, Second-line therapy or greater, Unresectable/Inoperable, Late-stage disease, Metastatic disease) in China (PO), in November 2024 (NCT06679036, HRS-2189-201-BC)
  • 04 Dec 2023 Phase-I clinical trials in Solid tumours (Late-stage diseases) (PO), prior to December 2023 (Shanghai Hengrui Medicine pipeline, December 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top